专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08906955B2 Use of adrenergic beta-3-receptor agonists in anti-aging 有权
标题翻译：肾上腺素能β-3-受体激动剂在抗衰老中的应用
公开(公告)号：US08906955B2
公开(公告)日：2014-12-09
申请号：US13754600
申请日：2013-01-30
申请人： Shuguang Lin , Meng Zheng
发明人： Shuguang Lin , Meng Zheng
IPC分类号： A61K31/38 , A61K31/335 , A61K31/36 , A61K31/19 , A61K31/18 , A61K31/195 , A61K31/138 , A61K31/357 , A61K31/426
CPC分类号： A61K31/195 , A61K31/138 , A61K31/18 , A61K31/357 , A61K31/36 , A61K31/426
摘要： A method for treating an aging-related disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor agonist.
摘要翻译：公开了治疗老化相关疾病的方法，其包括向受试者施用包含肾上腺素能β-3-受体激动剂的药物组合物。

2. 发明申请

US20130197091A1 USE OF ADRENERGIC BETA-E-RECEPTOR BLOCKERS IN CANCER TREATMENT 审中-公开
标题翻译：在癌症治疗中使用ADR-EIC受体阻断剂
公开(公告)号：US20130197091A1
公开(公告)日：2013-08-01
申请号：US13754633
申请日：2013-01-30
申请人： Shuguang LIN , Meng ZHENG
发明人： Shuguang LIN , Meng ZHENG
IPC分类号： A61K31/195 , A61K31/138
CPC分类号： A61K31/195 , A61K31/138 , A61K31/47
摘要： A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.
摘要翻译：公开了一种治疗癌症疾病的方法，其包括向受试者施用包含肾上腺素能β-3-受体阻断剂的药物组合物。

3. 发明授权

US11524073B2 Anti-human ADRB3 monoclonal antibody and application thereof in disease diagnosis and treatment 有权
公开(公告)号：US11524073B2
公开(公告)日：2022-12-13
申请号：US15933406
申请日：2018-03-23
申请人： Meng Zheng , Shuguang Lin
发明人： Meng Zheng , Shuguang Lin
IPC分类号： C07K16/28 , A61K39/395 , C07K14/705 , G01N33/74 , A61P25/36 , A61P3/10 , A61P37/00 , A61P35/00 , G01N33/94 , A61P15/10 , A61P31/12 , A61P25/18 , G01N33/569 , C07K14/725 , G01N33/574 , G01N33/577 , G01N33/68 , A61K39/00
摘要： The present invention discloses an application of a β3 adrenergic receptor (ADRB3) as a marker for detecting a plurality of diseases, and an application of anti-human ADRB3 monoclonal antibody in diagnosing a disease and preparing a drug for treating the disease. The present invention finds through research that the ADRB3 is a key receptor in nerve-endocrine-immunoregulatory network, and an ADRB3-mediated signaling pathway regulates proliferation and differentiation of neutrophils, lymphocytes and tumor cells. Under normal circumstances, the ADRB3 maintains the non-specific immunocompetence and specific immunocompetence of an organism, and eliminates pathogenic microorganisms and aged organism tissues to play a role in protecting the organism and anti-aging. Under pathological conditions, excessive activation of the signaling pathway will cause systemic chronic inflammation, and destroy immune homeostasis. Therefore, the ADRB3 can be used as a diagnostic marker and a therapeutic target for a plurality of diseases. Anti-human ADRB3 antibody can specifically bond with the ADRB3, regulate the activity of the ADRB3, has the functions of resisting cancer, inflammation, poisoning, shock, allergy, viral infection, autoimmune disease, disease caused by regenerative dysfunction, autoimmune disease, cachexia, cardiovascular and cerebrovascular disease, neurodegenerative disease and aging, regulating autophagy, treating aging disease, etc., and has important medical value and research and application prospects.

4. 发明申请

US20180355037A1 ANTI-HUMAN ADRB3 MONOCLONAL ANTIBODY AND APPLICATION THEREOF IN DISEASE DIAGNOSIS AND TREATMENT 审中-公开
公开(公告)号：US20180355037A1
公开(公告)日：2018-12-13
申请号：US15933406
申请日：2018-03-23
申请人： Meng ZHENG , Shuguang LIN
发明人： Meng ZHENG , Shuguang LIN
IPC分类号： C07K16/28 , G01N33/68 , G01N33/577 , C07K14/705 , G01N33/574 , C07K14/725
CPC分类号： C07K16/286 , A61K2039/505 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70571 , C07K14/70578 , C07K16/2869 , C07K2317/565 , C07K2319/00 , G01N33/57484 , G01N33/577 , G01N33/6893 , G01N33/6896 , G01N33/74 , G01N33/9433 , G01N2333/70571 , G01N2333/726
摘要： The present invention discloses an application of a J33 adrenergic receptor (ADRB3) as a marker for detecting a plurality of diseases, and an application of anti-human ADRB3 monoclonal antibody in diagnosing a disease and preparing a drug for treating the disease. The present invention finds through research that the ADRB3 is a key receptor in nerve-endocrine-immunoregulatory network, and an ADRB3-mediated signaling pathway regulates proliferation and differentiation of neutrophils, lymphocytes and tumor cells. Under normal circumstances, the ADRB3 maintains the non-specific immunocompetence and specific immunocompetence of an organism, and eliminates pathogenic microorganisms and aged organism tissues to play a role in protecting the organism and anti-aging. Under pathological conditions, excessive activation of the signaling pathway will cause systemic chronic inflammation, and destroy immune homeostasis. Therefore, the ADRB3 can be used as a diagnostic marker and a therapeutic target for a plurality of diseases. Anti-human ADRB3 antibody can specifically bond with the ADRB3, regulate the activity of the ADRB3, has the functions of resisting cancer, inflammation, poisoning, shock, allergy, viral infection, autoimmune disease, disease caused by regenerative dysfunction, autoimmune disease, cachexia, cardiovascular and cerebrovascular disease, neurodegenerative disease and aging, regulating autophagy, treating aging disease, etc., and has important medical value and research and application prospects.

5. 发明授权

US09622996B2 Use of adrenergic beta-E-receptor blockers in cancer treatment 有权
公开(公告)号：US09622996B2
公开(公告)日：2017-04-18
申请号：US13754633
申请日：2013-01-30
申请人： Shuguang Lin , Meng Zheng
发明人： Shuguang Lin , Meng Zheng
IPC分类号： A61K31/195 , A61K31/47 , A61K31/138
CPC分类号： A61K31/195 , A61K31/138 , A61K31/47
摘要： A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.

6. 发明申请

US20140187263A1 BASE STATION AND CONTROL METHOD THEREOF 审中-公开
标题翻译：基站及其控制方法
公开(公告)号：US20140187263A1
公开(公告)日：2014-07-03
申请号：US14238077
申请日：2012-07-25
申请人： Lu Geng , Meng Zheng , Hideya Yoshiuchi
发明人： Lu Geng , Meng Zheng , Hideya Yoshiuchi
IPC分类号： H04W4/02
CPC分类号： H04W64/00 , H04B7/024 , H04J11/0056 , H04J2211/001 , H04W16/08 , H04W72/04 , H04W72/048 , H04W72/10
摘要： A base station and control method thereof for wireless communication network is provided. The base station comprises: transceiver unit for transmitting and receiving of data with communication nodes and terminals; location information storage unit for storing location information of the terminal in the wireless communication network; range expanding condition information storage unit for storing range expanding condition information of respective communication node which each terminal corresponding to; and control unit for determining a service strategy for the terminals based at least on the location information of the terminal in the wireless communication network and the range expanding condition information of respective communication node which each terminal corresponding to. It is expected to give full play to advantages of eICIC and CoMP for the real channel state of different terminals, achieve combination or conversion between them, so as to optimize the overall network design.
摘要翻译：提供了一种用于无线通信网络的基站及其控制方法。该基站包括：用于与通信节点和终端发送和接收数据的收发单元; 位置信息存储单元，用于存储无线通信网络中终端的位置信息; 范围扩展条件信息存储单元，用于存储每个终端对应的各个通信节点的扩展条件信息; 以及控制单元，用于至少基于无线通信网络中的终端的位置信息以及每个终端对应的各个通信节点的扩展条件信息来确定终端的服务策略。充分发挥eICIC和CoMP的优势，实现不同终端的实际通道状态，实现组合或转换，从而优化整体网络设计。

7. 发明申请

US20130197074A1 USE OF ADRENERGIC BETA-3-RECEPTOR AGONISTS IN ANTI-AGING 有权
标题翻译：在抗衰老中使用ADRENERGIC BET-3受体激动剂
公开(公告)号：US20130197074A1
公开(公告)日：2013-08-01
申请号：US13754600
申请日：2013-01-30
申请人： Shuguang LIN , Meng ZHENG
发明人： Shuguang LIN , Meng ZHENG
IPC分类号： A61K31/195 , A61K31/138
CPC分类号： A61K31/195 , A61K31/138 , A61K31/18 , A61K31/357 , A61K31/36 , A61K31/426
摘要： A method for treating an aging-related disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor agonist.
摘要翻译：公开了治疗老化相关疾病的方法，其包括向受试者施用包含肾上腺素能β-3-受体激动剂的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式